40
CARDIOGENIC SHOCK Faculty of Medicine University of Brawijaya

Cardiogenic Shock

Embed Size (px)

DESCRIPTION

kuliah patofisiologi syok kardiogenik dan terapi tentang syok kardiogenik

Citation preview

Page 1: Cardiogenic Shock

CARDIOGENIC SHOCKFaculty of Medicine

University of Brawijaya

Page 2: Cardiogenic Shock

DEFINIDEFINITIONTION of SHOCK of SHOCK

IT IS NOT LOW BLOOD PRESSURE !!!IT IS HYPOPERFUSION…..

Disorder of tissue perfusion as a result of imbalance between oxygen supply to and oxygen demand of the cells.

All types of shock result in tissue perfusion disorder, which may develop acute circulatory failure or it is also called shock syndrome

Page 3: Cardiogenic Shock

TTYPES OF SHOCKYPES OF SHOCK**

 Type of Shock  Clinical causes Primary mechanism

 Hypovolemic

 Volume loss

 Exogenous blood, plasma, fluid or electrolyte loss

CardiogenicPump failure

Myocardial infarction, cardiac arrhythmias, heart failure

Distributive

Increased venous capacitance or arteriovenous shunting

Septic shock, spinal shock, autonomic blockade, drug overdose 

Obstructive

Extra-cardiac obstruction of blood flow

Vena caval obstruction, cardiac tamponade, pulmonary embolism, aortic compression or dissection

**MORE THAN ONE TYPE MAY BE PRESENTMORE THAN ONE TYPE MAY BE PRESENT

Page 4: Cardiogenic Shock

DEFINITION OF CARDIOGENIC SHOCK

Systolic BP < 90 mm Hg, or 30 mm Hg below baseline for at least 30 mins, evidence of poor tissue perfusion and persistence of shock after correction of non-myocardial factors (eg hypovolaemia, hypoxia, acidosis, arrhythmias)

Page 5: Cardiogenic Shock

CRITERIA FOR CARDIOGENIC SHOCK DIAGNOSIS

<90 mmHg

<2.2 li/min.m2

>15 mmHg

Page 6: Cardiogenic Shock

SHOCK REGISTRY JACC SEPT. 2000, SUPP. A

SPECTRUM OF CLINICAL PRESENTATIONS

MortalityRespiratory

DistressHypotension Hypoperfusion

21%

22%

70%

60%

5.6%

28%

65%

1.4%

Page 7: Cardiogenic Shock

RISK FACTORS FOR CARDIOGENIC SHOCK DUE TO AMI [ACUTE MYOCARD INFARCT]-MEDIATED LV DYSFUNCTION…

Age > 65 Female gender Large infarction Anterior infarction Prior infarction DM (diabetes mellitus) Prior HTN (hypertension)

Page 8: Cardiogenic Shock

POST-MORTEM STUDY OF SHOCK HEARTS

At least 40% of the myocardium infarcted in the aggregate (old and new injury)

80% have significant LAD (left anterior descendent) disease

2/3 have severe 3Vdz (three vessel disease)

Page 9: Cardiogenic Shock

OUTCOMES OF CARDIOGENIC SHOCK

Historic mortality 60-80%

More recently reported mortality numbers 67% in the SHOCK trial registry 56% in GUSTO-I

(v.s. 3% in Pts. without shock)

Page 10: Cardiogenic Shock

OUTCOMES OF CARDIOGENIC SHOCK

The ST pattern in Cardiogenic shock: 15-30 % Non-ST elevation MI

OlderMortality: 77%

70-85% ST elevations MI/ New LBBBMortality: 53-63%

Page 11: Cardiogenic Shock

OUTCOMES OF CARDIOGENIC SHOCK

The SHOCK registry

Similar mortality in the two groups62.5% in non-ST elevation60.4% with ST elevation

Page 12: Cardiogenic Shock

AETIOLOGY OF CARDIOGENIC SHOCK

myocardial infarction including complications of myocardial infarction (eg acute mitral regurgitation, VSD, free wall rupture, LV aneurysm)

end-stage cardiomyopathy myocardial contusion myocarditis LV outflow obstruction (HOCM, aortic stenosis) LV inflow obstruction (mitral stenosis, LA myxoma) sequela of cardiopulmonary bypass

Page 13: Cardiogenic Shock

ETIOLOGIES OF CARDIOGENIC SHOCK Acute myocardial

infarction/ischemia  LV failure  VSR (ventricular

septal rupture) Papillary

muscle/chordal rupture- severe MR (mitral regurgitation)

Ventricular free wall rupture with subacute tamponade 

Other conditions complicating large MIs   Hemorrhage  Infection   Excess negative inotropic

or vasodilator medications   Prior valvular heart

disease   Hyperglycemia/ketoacidosis Post-cardiac arrest Post-cardiotomy Refractory sustained

tachyarrhythmias Acute fulminant

myocarditis End-stage

cardiomyopathyHypertrophic cardiomyopathy with severe outflow obstruction

Aortic dissection with aortic insufficiency or tamponade

Pulmonary embolu Severe valvular heart

disease -Critical aortic or mitral stenosis, Acute severe aortic or MR

Page 14: Cardiogenic Shock

PATHOPHYSIOLOGY Compensatory mechanisms such as salt &

water retention and peripheral vasoconstriction tend to exacerbate LV dysfunction.

Also decreased perfusion pressure, especially in the presence of multi-vessel coronary disease leads to further depression of myocardial contractility.

Page 15: Cardiogenic Shock

PATHOPHYSIOLOGY OF SHOCK

Effect of:

Elevated LVEDP on coronary flow

LVEDP(mm Hg)

Page 16: Cardiogenic Shock

PATHOPHYSIOLOGY OF SHOCK

Hypotension + LVEDP and critical stenosis Myocardial Hypoperfusion LV dysfunction Systemic lactic acidosis Impairment of non-ischemic myocardium worsening hypotension.

Page 17: Cardiogenic Shock

SCHEMATIC

LVEDP elevationHypotensionDecreased coronary perfusionIschemiaFurther myocardial dysfunctionNeurohormonal activation VasoconstrictionEnd-organ hypoperfusion

Page 18: Cardiogenic Shock

CLINICAL FINDINGS Physical Exam: elevated JVP, +S3, rales,

oliguria, acute pulmonary edema

Hemodynamics: decreased CO (cardiac output), increased SVR (systemic vascular resistance), decreased SvO2 (oxygen saturation)

Initial evaluation: hemodynamics (PA [pulmonary artery] catheter), echocardiography, angiography

Page 19: Cardiogenic Shock

INVESTIGATIONS

Echo for all patients to exclude surgically correctable lesion and tamponade and to look for RV infarction

ECG: normal ECG virtually excludes possibility of cardiogenic shock caused by MI (myocardial infarction)

Page 20: Cardiogenic Shock

DIFFERENTIAL DIAGNOSIS OF CARDIOGENIC SHOCK

AMI (acute myocard infarct)PE (pulmonary embolism)COPD (chronic obstructive pulmonary

disease)PneumoniaAortic dissectionTamponadeAcute valvular insufficiencyHemorrhageSepsisDrug OD (over dosage) of negative

inotropic/chronotropic agent

Page 21: Cardiogenic Shock

4 POTENTIAL THERAPIES

Pressors Intra-aortic Balloon Pump (IABP) Fibrinolytics Revascularization: CABG (coronary artery

bypass grafting)/PCI (Per Cutaneous Coronary Intervention)

Refractory shock: ventricular assist device, cardiac transplantation

Page 22: Cardiogenic Shock

TREATMENT OF CARDIOGENIC SHOCK

optimize preload and afterload. Vasodilators should be given with extreme caution.

Nitroprusside may cause coronary steal. Vasodilators particularly important

when mitral regurgitation is a major contributing factor

Page 23: Cardiogenic Shock

TREATMENT (CONTINUED….)

inotropes. Dobutamine unless shock is profound in which case drugs with vasoconstrictor actions preferable. Phosphodiesterase inhibitors should be reserved for those in whom catecholamines have failed to improve cardiac performance or those in whom arrhythmia or ischaemia limits catecholamine dose

intra-aortic balloon pump. Only of value if subsequent revascularization is possible

Page 24: Cardiogenic Shock

TREATMENT (CONTINUED…)

thrombolysis. No definite evidence that this alters prognosis. May be less effective in patients with cardiogenic shock because of poor coronary blood flow. Combination of thrombolysis and IABP may be more effective. Mortality higher in those treated with t-PA compared to those treated with streptokinase

Page 25: Cardiogenic Shock

TREATMENT (CONTINUED…..)

PTCA (Percutaneous transluminal coronary angioplasty). Probably treatment of choice in cases due to IHD (ischemic heart disease). Both PTCA and CABG need to be performed within first few hours (ideally within 2-4 h) of onset of symptoms. Result in improved survival at 6 months and 1 year although not at 30 days

Page 26: Cardiogenic Shock

TREATMENT (

CABG (coronary artery bypass grafting). May be of benefit if facilities immediately available. Operative mortality is high

Page 27: Cardiogenic Shock

TREATMENT

Patients with RV infarction leading to cardiogenic shock particularly sensitive to volume depletion and prone to deterioration from bradycardia and loss of AV synchrony due to advanced heart block. Focus of therapy should be immediate restoration of adequate LV filling pressure, maintenance of sinus rhythm or synchronized pacing and use of dobutamine to stimulate RV systolic function

Page 28: Cardiogenic Shock

PRESSORS DO NOT CHANGE OUTCOME

Dopamine <2 micro - gram /kg BW/ minutes, renal vascular dilation <2-10 micro - gram /kg BW/ minutes +chronotropic/inotropic (beta

effects) >10 micro - gram /kg BW/ minutes : vasoconstriction (alpha effects)

Dobutamine – positive inotrope, vasodilates, arrhythmogenic at higher doses

Norepinephrine (Levophed): vasoconstriction, inotropic stimulant. Should only be used for refractory hypotension with decreased SVR.

Vasopression – vasoconstriction VASO and LEVO should only be used as a

last resort

Page 29: Cardiogenic Shock

IABP (INTRA AORTIC BALLOON PUMP) IS A TEMPORIZING MEASURE

Augments coronary blood flow in diastole

Balloon collapse in systole creates a vacuum effect decreases afterload

Decrease myocardial oxygen demand

Page 30: Cardiogenic Shock

Intra-Aortic Balloon Pump

Page 31: Cardiogenic Shock

INDICATION FOR IABP

Page 32: Cardiogenic Shock

CONTRAINDICATIONS TO IABP

Significant aortic regurgitation or significant arteriovenous shunting

Abdominal aortic aneurysm or aortic dissection

Uncontrolled sepsis Uncontrolled bleeding disorder Severe bilateral peripheral vascular disease Bilateral femoral popliteal bypass grafts for

severe peripheral vascular disease.

Page 33: Cardiogenic Shock

COMPLICATIONS OF IABP

Cholesterol Embolization CVA (cerebro vascular accident) Sepsis Balloon rupture Thrombocytopenia Hemolysis Groin Infection Peripheral Neuropathy

Page 34: Cardiogenic Shock

HOCM (HYPERTROPHIC OBSTRUCTIVE CARDIOMYPATHY)

usual methods used to treat cardiogenic shock exacerbate obstruction

plasma volume expansion and IV titration of beta-blockers reduce ventricular outflow obstruction and improve cardiac output

Page 35: Cardiogenic Shock

PROGNOSIS OF PATIENTS WITH CARDIOGENIC SHOCK

poor only about 1/3 of patients actively

treated survive initial episode and many of the survivors have continuing angina, CCF and decreased exercise tolerance

approximately 1/2 with a surgically correctable lesion leave hospital

RV function usually returns to normal in survivors of cardiogenic shock associated with RV infarction

Page 36: Cardiogenic Shock

PROGNOSIS 50% of patients who require maximal

therapy and IABP to come off bypass die. If ventricular assist device also required then only 35-45% survive. Functional prognosis for these survivors quite good

Mortality without aggressive highly technical care is 70-90%. Hospitals without the facilities for IABP or high-risk angioplasty and surgical intervention should begin initial resuscitative measures and then make a rapid decision about transfer to a hospital with the necessary resources

Page 37: Cardiogenic Shock

Myocardial Myocardial stunning and stunning and hibernationhibernation

Page 38: Cardiogenic Shock

MYOCARDIAL STUNNING Mechanical dysfunction of myocardium which

persists despite absence of irreversible damage and restoration of normal or near-normal coronary flow and which recovers spontaneously.

Clinically important in 3 settings: - after MI (especially after thrombolysis or primary

angioplasty) - after complicated coronary interventions (when

myocardium may be ischaemic for long periods, particularly if there is pre-existing LV dysfunction)

- after cardiac surgery Mechanical circulatory support may be preferable

to inotropes for patients with stunned myocardium as inotropes may adversely influence recovery of potentially ischaemic segments

Page 39: Cardiogenic Shock

HIBERNATING MYOCARDIUM

Myocardium with impaired function that is persistently impaired at rest due to decreased coronary blood flow but which demonstrates improved function when balance between oxygen supply and demand is improved.

Dobutamine echocardiography can be used to differentiate between stunned myocardium with a patent artery ( function that persists during infusion) from stunned myocardium with a stenosed artery or hibernation (initial followed by deterioration).

Page 40: Cardiogenic Shock